Targeting HER2 in the treatment of non-small cell lung cancer

Lung Cancer

Volumn 87, Issue 3, 2015, Pages 220-225

  Mar, Nataliya ^a   Vredenburgh, James J ^b   Wasser, Jeffrey S ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b Department of Hematology Oncology CT   (United States)

Author keywords

Driver mutation; HER2 gene amplification; HER2 gene mutation; HER2 protein overexpression; HER2 targeted therapy; Lung adenocarcinoma

Indexed keywords

AFATINIB; BUPARLISIB; CISPLATIN; CIXUTUMUMAB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEMCITABINE; LAPATINIB; MARGETUXIMAB; NERATINIB; PERTUZUMAB; TEMSIROLIMUS; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER THERAPY; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MEDICAL DECISION MAKING; MOLECULAR THERAPY; MONOTHERAPY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROGNOSIS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84924054240     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.12.018     Document Type: Review

References (63)

1. Cancer Fact Sheet #297 World Health Organization 2014, Available online at http://www.who.int/mediacentre/factsheets/fs297/en [accessed 15.12.14].
2. Surveillance, Epidemiology and End Results Program SEER stat fact sheets: lung and bronchus cancer 2014, National Cancer Institute, Available online at http://seer.cancer.gov/statfacts/html/lungb.html [accessed 28.09.14].
3. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83(May (5)):584-594.
4. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136(July (1)):260-271.
5. Stratton M.R., Campbell P.J., Futreal A. The cancer genome. Nature 2009, 458(April (7239)):719-724.
6. Oxnard G.R., Binder A., Jänne P.A. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013, 31(March (8)):1097-1104.
7. Scholl S., Beuzeboc P., Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001, 12(Suppl. 1):S81-S87.
8. Perera S.A., Li D., Shimamura T., Raso M.G., Ji H., Chen L., et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA 2009, 106(January (2)):474-479.
9. Peters S., Zimmermann S. Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res 2014, 3(April (2)).
10. Kuyama S., Hotta K., Tabata M., Segawa Y., Fujiwara Y., Takigawa N., et al. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol 2008, 3(May (5)):477-482.
11. Pallis A.G., Syrigos K.N. Lung cancer in never smokers: disease characteristics and risk factors. Crit Rev Oncol Hematol 2013 Dec, 88(3):494-503.
12. Arcila M.E., Chaft J.E., Nafa K., Roy-Chowdhuri S., Lau C., Zaidinski M., et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012, 18(September (18)):4910-4918.
13. Takezawa K., Pirazzoli V., Arcila M.E., Nebhan C.A., Song X., de Stanchina E., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012, 2(October (10)):922-933.
14. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. journal of clinical oncology (J Clin Oncol) 2009, 27(December (34)):5838-5847.
15. Garrido-Castro A.C., Felip E. HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. Transl Lung Cancer Res 2013, 2(April (2)).
16. Mazières J., Peters S., Lepage B., Cortot A.B., Barlesi F., Beau-Faller M., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013, 31(June (16)):1997-2003.
17. Greulich H., Kaplan B., Mertins P., Chen T.H., Tanaka K.E., Yun C.H., et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 2012, 109(September (36)):14476-14481.
18. Yamamoto H., Higasa K., Sakaguchi M., Shien K., Soh J., Ichimura K., et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst 2014, 106(January (1)). djt338.
19. Hirsch F.R., Varella-Garcia M., Franklin W.A., Veve R., Chen L., Helfrich B., et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002, 86(May (9)):1449-1456.
20. Zimmermann S., Peters S. Going beyond EGFR. Ann Oncol 2012, 23(September (Suppl. 10)):x197-x203.
21. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12(February (2)):175-180.
22. Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431(September (7008)):525-526.
23. Zinner R.G., Glisson B.S., Fossella F.V., Pisters K.M., Kies M.S., Lee P.M., et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004, 44(April (1)):99-110.
24. Heinmöller P., Gross C., Beyser K., Schmidtgen C., Maass G., Pedrocchi M., et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 2003, 9(November (14)):5238-5243.
25. Fornier M.N., Seidman A.D., Schwartz M.K., Ghani F., Thiel R., Norton L., et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005, 16(February (2)):234-239.
26. Leyland-Jones B., Smith B.R. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol 2011, 12(March (3)):286-295.
27. Gown A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008, 21(May (Suppl. 2)):S8-S15.
28. Roche P.C., Suman V.J., Jenkins R.B., Davidson N.E., Martino S., Kaufman P.A., et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002, 94(June (11)):855-857.
29. Press M.F., Sauter G., Bernstein L., Villalobos I.E., Mirlacher M., Zhou J.Y., et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005, 11(September (18)):6598-6607.
30. Press M.F., Slamon D.J., Flom K.J., Park J., Zhou J.Y., Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002, 20(July (14)):3095-3105.
31. Clark B.Z., Bhargava R. Bright-field microscopy for HER2 gene assessment - not just DISH-ful thinking?. Am J Clin Pathol 2013, 139(February (2)):137-139.
32. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21(October (20)):3798-3807.
33. Mansfield A.S., Sukov W.R., Eckel-Passow J.E., Sakai Y., Walsh F.J., Lonzo M., et al. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. Am J Clin Pathol 2013, 139(February (2)):144-150.
34. U.S.Food and Drug Administration INFORM HER2 dual ISH DNA probe cocktail - P100027 2011, Available online at http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm259302.htm [accessed 28.09.14].
35. Yoshizawa A., Sumiyoshi S., Sonobe M., Kobayashi M., Uehara T., Fujimoto M., et al. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer 2014, 85(September (3)):373-378.
36. Metzker M.L. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11(January (1)):31-46.
37. Ross J.S., Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol 2011, 136(October (4)):527-539.
38. Tan D., Deeb G., Wang J., Slocum H.K., Winston J., Wiseman S., et al. HER/2neu protein expression and gene alteration in stage I-IIIA non-small cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry and fluorescent in situ hybridization. Diagn Mol Pathol 2003, 12(December (4)):201-211.
39. Liu L., Shao X., Gao W., Bai J., Wang R., Huang P., et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010, 5(December (12)):1922-1932.
40. Swanton C., Futreal A., Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 2006, 12(July (14 Pt 2)):4377s-4383s.
41. Tomizawa K., Suda K., Onozato R., Kosaka T., Endoh H., Sekido Y., et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 2011, 74(October (1)):139-144.
42. Giordano S.H., Temin S., Kirshner J.J., Chandarlapaty S., Crews J.R., Davidson N.E., et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol 2014, 32(July (19)):2078-2099.
43. Gatzemeier U., Groth G., Butts C., Van Zandwijk N., Shepherd F., Ardizzoni A., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004, January (15)(1):19-27.
44. Lara P.N., Laptalo L., Longmate J., Lau D.H., Gandour-Edwards R., Gumerlock P.H., et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California cancer consortium screening and phase II trial. Clin Lung Cancer 2004, 5(January (4)):231-236.
45. Langer C.J., Stephenson P., Thor A., Vangel M., Johnson D.H. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on eastern cooperative oncology group study 2598. J Clin Oncol 2004, 22(April (7)):1180-1187.
46. Clamon G., Herndon J., Kern J., Govindan R., Garst J., Watson D., et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia group B. Cancer 2005, 103(April (8)):1670-1675.
47. Wang S.E., Narasanna A., Perez-Torres M., Xiang B., Wu F.Y., Yang S., et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10(July (1)):25-38.
48. Cappuzzo F., Bernis L., Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006, 354(June (24)):2619-2621.
49. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L., et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005, 23(August (22)):5007-5018.
50. De Grève J., Teugels E., Geers C., Decoster L., Galdermans D., De Mey J., et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012, 76(April (1)):123-127.
51. National Comprehensive Cancer Network Non-small cell lung cancer (Version 4.2014) 2014, Available online at http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [accessed 28.09.14].
52. Janjigian Y.Y., Smit E.F., Groen H.J., Horn L L., Gettinger S., Camidge D.R., et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 2014, 4(September (9)):1036-1045.
53. Tsang R.Y., Finn R.S. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012, 106(January (1)):6-13.
54. Shimamura T., Ji H., Minami Y., Thomas R.K., Lowell A.M., Shah K., et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 2006, 66(July (13)):6487-6491.
55. Suzuki T., Fujii A., Ohya J., Amano Y., Kitano Y., Abe D., et al. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Sci 2007, 98(December (12)):1977-1984.
56. Reckamp K.L., Giaccone G., Camidge D.R., Gadgeel S.M., Khuri F.R., Engelman J.A., et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 2014, 120(April (8)):1145-1154.
57. Gandhi L., Bahleda R., Tolaney S.M., Kwak E.L., Cleary J.M., Pandya S.S., et al. I Phase study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 2014, 32(January (2)):68-75.
58. Besse B., Soria J.-C., Yao B. Neratinib with or without temsirolimus in patients with non-small cell lung cancer carrying HER2 somatic mutations: an international randomized phase II study. ESMO Cong 2014, Abstract LBA39_PR. Presented September 29, 2014.
59. Swain S.M., Kim S.B., Cortés J., Ro J., Semiglazov V., Campone M., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14(May (6)):461-471.
60. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13(January (1)):25-32.
61. Phillips G.D., Fields C.T., Li G., Dowbenko D., Schaefer G., Miller K., et al. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 2014, 20(January (2)):456-468.
62. Lin N.U., Diéras V., Paul D., Lossignol D., Christodoulou C., Stemmler H.J., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15(February (4)):1452-1459.
63. Bachelot T., Romieu G., Campone M., Diéras V., Cropet C., Dalenc F., et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013, 14(January (1)):64-71.